Brett E Crawford

This inventor holds 15 USPTO granted patents and 8 published patent applications, plus 3 CIPO patents and 4 EPO patents. Top assignees: Biomarin Pharmaceutical Inc., Zacharon Pharmaceuticals, Inc.. Active years: 2012-2020.

USPTO Granted Patents = 15 (Patent Applications = 8)

% Patents Active = 93.3

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 4 (Patent Applications = 10)

Average Co-Inventor Count = 4.1

ph-index = 7

Forward Citations = 110(Granted Patents)

Company Filing History:

13 out of 136

Biomarin Pharmaceutical Inc.

patents

2 out of 2

Zacharon Pharmaceuticals, Inc.

patents

Years Active: 2012-2020

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10793894 - Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition (2020-10-06),

2. 10683530 - Detection of oligosaccharides (2020-06-16),

3. 10677786 - Methods of diagnosing mucopolysaccharidosis (MPS) I and methods of monitoring treatment of MPS by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker (2020-06-09),

4. 10260084 - Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition (2019-04-16),

5. 9915649 - Methods of determining the presence, identity, and/or severity of mucopolysaccharidosis (MPS) VI and IVA (2018-03-13),

6. 9796999 - Detection of oligosaccharides (2017-10-24),

7. 9677116 - Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition (2017-06-13),

8. 9340822 - Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker (2016-05-17),

9. 9222120 - Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition (2015-12-29),

10. 9029530 - Detection of oligosaccharides (2015-05-12),

11. 8809009 - Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker (2014-08-19),

12. 8771974 - Methods of determining the presence and/or amount of a biomarker to determine the presence, identity, and/or severity of a lysosomal storage or neurological disorder (2014-07-08),

13. 8592140 - Detection of oligosaccharides (2013-11-26),

14. 8232073 - Quantification of non-reducing end glycan residual compounds (2012-07-31),

15. 8183003 - Polymer end group detection (2012-05-22),

Title: The Inventive Journey of Brett E Crawford

Introduction:

Brett E Crawford, a prolific inventor hailing from Poway, CA, has made significant contributions to the field of biomedical research with a total of 15 patents to his name. His innovative work focuses on the quantification of non-reducing end glycan residual compounds and the detection of oligosaccharides for the diagnosis and monitoring of various diseases.

Latest Patents:

Among his latest patents is the groundbreaking method for quantifying non-reducing end glycan residual compounds to determine the presence, identity, or severity of a disease. Additionally, his invention includes a process for detecting oligosaccharides in biological samples, especially in individuals suffering from disorders associated with abnormal glycosaminoglycan accumulation.

Career Highlights:

Brett E Crawford has been associated with prestigious companies such as Biomarin Pharmaceutical Inc. and Zacharon Pharmaceuticals, Inc., where he has played a key role in driving innovation and advancing healthcare solutions through his patented inventions.

Collaborations:

Throughout his career, Brett E Crawford has collaborated with esteemed colleagues such as Charles A Glass and Jillian R Brown. Together, they have worked towards developing cutting-edge technologies aimed at improving diagnostic and therapeutic approaches in the field of biomedicine.

Conclusion:

In conclusion, Brett E Crawford's innovative spirit and relentless dedication to healthcare innovation have led to groundbreaking advancements in the field of biomedicine. His patents and collaborations stand as a testament to his commitment to improving the lives of individuals affected by various diseases and disorders.